Broaden Bioscience

Broaden Bioscience is a biotechnology company specializing in the discovery and development of next-generation covalent small molecule therapeutics. Utilizing its proprietary chemoproteomics platform, Broaden-CP, the company identifies novel binding pockets on "undruggable" targets to develop highly selective covalent inhibitors. Their research primarily focuses on oncology and immunology, aiming to overcome resistance mechanisms and improve therapeutic indices for challenging disease drivers. The company integrates structural biology, computational chemistry, and high-throughput covalent screening to accelerate its drug discovery pipeline from its dual bases in Shanghai and Cambridge.